Erik Kinnman

Directeur Général chez VIVESTO AB

Profil

Erik Kinnman is currently Chief Executive Officer at Vivesto AB since 2023, Co-Chairman at Edvince AB, Chairman at Kinnman Solutions AB since 2016, Director at Stayble AB, and Independent Director at ISR Immune System Regulation Holding AB since 2022.
Former roles include Chief Executive Officer at Abliva AB from 2016 to 2021, Chief Executive Officer at Sprint Bioscience AB from 2021 to 2023, Chief Strategic Officer & Director-IR at Biovitrum AB in 2010, VP-Investor Relations & Director-Business Strategy at Egetis Therapeutics AB, Director at Stayble Therapeutics AB from 2020 to 2026, Associate Professor at Karolinska Institutet, Analyst at Danske Bank A, Chief Strategic Officer & Vice President at Swedish Orphan Biovitrum AB from 2008 to 2011, and Chief Medical Officer at Infant Bacterial Therapeutics AB from 2014 to 2016.
Education includes a doctorate from Karolinska Institutet and an MBA from Stockholm School of Economics.

Postes actifs de Erik Kinnman

Sociétés	Poste	Début
ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)	Directeur/Membre du Conseil	01/01/2022
VIVESTO AB	Directeur Général	23/01/2023
Kinnman Solutions AB	Président	01/01/2016
Stayble AB	Directeur/Membre du Conseil	-
Edvince AB	Président	-

Anciens postes connus de Erik Kinnman

Sociétés	Poste	Fin
STAYBLE THERAPEUTICS AB	Directeur/Membre du Conseil	21/05/2026
SPRINT BIOSCIENCE AB	Directeur Général	01/01/2023
ABLIVA AB	Directeur Général	03/02/2021
INFANT BACTERIAL THERAPEUTICS AB	Directeur Technique/Scientifique/R&D	01/01/2016
░░░░░░░ ░░░░░░ ░░░░░░░░░ ░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░